Ulf Bohlmann

Title: Ulf Bohlmann: Innovator in Pharmaceuticals

Introduction

Ulf Bohlmann, based in Köln, Germany, is a notable inventor recognized for his contributions to the pharmaceutical industry. With a strong focus on innovative methods for drug development, he has made significant strides in enhancing the stability and manufacturability of pharmaceutical compounds.

Latest Patents

Ulf Bohlmann holds a patent for a method of preparing 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde (E)-oxime, commonly known as asoprisnil. This patent outlines a reliable and reproducible approach to synthesize asoprisnil on both pilot and manufacturing scales. The resultant compound is noted for its excellent physical stability, making it particularly suitable for the development of solid pharmaceutical forms including tablets and coated tablets.

Career Highlights

Bohlmann is currently employed at Bayer Pharma Aktiengesellschaft, one of the leading global pharmaceutical companies, where he leverages his expertise to drive innovation in drug formulation and stability. His contributions to Bayer Pharma have been pivotal in advancing the discovery and manufacture of effective pharmaceutical solutions.

Collaborations

Throughout his career, Ulf Bohlmann has worked alongside accomplished colleagues such as Detlef Grawe and Sabine Gliesing. This collaborative environment has fostered a culture of innovation, leading to the successful development of new therapeutic agents.

Conclusion

Ulf Bohlmann stands out as a dedicated inventor in the field of pharmaceuticals. His patent on asoprisnil is a testament to his commitment to enhancing drug stability and manufacturability. As he continues to work at Bayer Pharma Aktiengesellschaft, his contributions are sure to make a lasting impact on the pharmaceutical landscape.